Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca CEO Says Post-Crestor Future On Track As Pipeline Builds

Executive Summary

AstraZeneca's first-half results presentation highlighted its growing early pipeline, notably in oncology, but also the increasing pain of generic erosion on its Crestor sales – underlining again the importance new drugs will play in the group's turnaround strategy.

You may also be interested in...



AstraZeneca’s Business Development Head Grady Outlines Strategy Mix

AstraZeneca’s total focus on its core therapy areas will ensure it keeps building external collaborations and doing deals to generate new therapies while maximizing revenues, but outright sales of non-core mature medicines are likely to be fewer going forward, according to the company’s head of business development.

Crestor Generics To Launch After 12-Day Delay

AstraZeneca's legal gambit results in almost two more weeks of sales for the statin even though the court ultimately agreed with FDA on labeling carve-out for orphan indication.

UK Pharma Chiefs To Helm Brexit Steering Committee

Sir Andrew Witty and Pascal Soriot, CEOs of GlaxoSmithKline and AstraZeneca, respectively, are to co-chair a new steering group along with George Freeman, the UK's life sciences minister. The group will address the challenges posed to the sector by the UK's decision to withdraw from the EU.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM003387

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel